Skip to content

Effects of Remimazolam versus Propofol Total Intravenous Anesthesia on Postoperative Anxiety in Patients Undergoing Thyroidectomy: A Randomized Controlled Study

Effects of Remimazolam versus Propofol Total Intravenous Anesthesia on Postoperative Anxiety in Patients Undergoing Thyroidectomy: A Randomized Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123801
Enrollment
Unknown
Registered
2026-04-29
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety

Interventions

Group Remimazolam:Anesthesia was induced and maintained using remimazolam. Induction: remimazolam 0.15–0.3 mg/kg + sufentanil 0.3–0.5 µg/kg + cisatracurium 0.15 mg/kg Maintenance: remimazolam 0.3–1.5
Group propofol:Anesthesia was induced and maintained with propofol. Induction:Propofol 1.5–2.5 mg/kg + Sufentanil 0.3–0.5 µg/kg + Cisatracurium 0.15 mg/kg Maintenance:Propofol 4–12 mg/kg/h + Remifenta

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.No surgical contraindications and undergoing thyroidectomy. 2.ASA physical status Grade I-III. 3.Aged 18 to 65 years. 4.Female gender. 5.Voluntary participation in this study

Exclusion criteria

Exclusion criteria: 1.History of alcoholism, drug addiction, or mental illness(patients taking long-term anxiolytics, antidepressants, and sedative-hypnotics). 2.History of drug allergy. 3.Patients with nausea, vomiting, gastroesophageal reflux, delayed gastric emptying, pyloric obstruction, etc. 4.Complicated with severe cerebral, cardiac, pulmonary, hepatic, or renal diseases. 5.Severe sensory deficits (e.g., visual or hearing impairment) or other conditions that prevent normal communication with investigators and thus affect evaluation.

Design outcomes

Primary

MeasureTime frame
Incidence of anxiety;Recovery time;

Secondary

MeasureTime frame
Anxiety Score; pain score;Recovery quality; Adverse events;Recovery quality;Sleep quality;Hemodynamics;Extubation time;

Countries

China

Contacts

Public ContactYoubo Zuo

Affiliated Hospital of North Sichuan Medical College

442687398@qq.com+86 138 0827 1734

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026